ALGN
Align Technology, Inc.
ALGN's fundamentals are strong and it looks cheap: trading at 24x earnings, below its usual 36x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ALGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
ALGN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ALGN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $167 | — |
| Current | 24x | $167 | — |
| Cheap | 25x | $173 | +3.5% |
| Fair | 35x | $242 | +45% |
| Expensive | 69x | $470 | +182% |
Historical ranges are pointers, not guarantees.
ALGN's PE is in its cheap range at 24x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ALGN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect ALGN's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ALGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.89 | +73% |
| Q3 2026 | $6.86 | +33% |
| Q2 2026 | $5.74 | -3.4% |
| Q1 2026 | $5.95 | +8.2% |
| Q4 2025 | $5.65 | +0.5% |
| Q3 2025 | $5.17 | -12% |
| Q2 2025 | $5.94 | +1% |
| Q1 2025 | $5.50 | -9.2% |
| Q4 2024 | $5.62 | -3.3% |
ALGN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ALGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +1.9% |
| Q2 2026 | $1.1B | +4.3% |
| Q1 2026 | $1B | +6.2% |
| Q4 2025 | $1B | +5.3% |
| Q3 2025 | $995.7M | +1.8% |
| Q2 2025 | $1B | -1.6% |
| Q1 2025 | $979.3M | -1.8% |
| Q4 2024 | $995.2M | +4% |
ALGN's revenue has grown year over year for five quarters in a row: $1B last quarter, up 1.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +7 points |
| Q2 2026 | 15% | -1.5 points |
| Q1 2026 | 14% | +0.3 points |
| Q4 2025 | 15% | +0.3 points |
| Q3 2025 | 9.7% | -6.9 points |
| Q2 2025 | 16% | +1.8 points |
| Q1 2025 | 13% | -2.1 points |
| Q4 2024 | 14% | -3.4 points |
ALGN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ALGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ALGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $137.9M | -18% |
| Q2 2026 | $157.1M | +47% |
| Q1 2026 | $120.3M | +339% |
| Q4 2025 | $187.3M | -29% |
| Q3 2025 | $169M | -28% |
| Q2 2025 | $107.2M | +0.7% |
| Q1 2025 | $27.4M | +42% |
| Q4 2024 | $263.1M | +1851% |
ALGN still generates free cash flow, though less than at its 2020 peak: $603M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ALGN on cash flow, with more consistent year-over-year improvement.
ALGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -505K shares |
| 1 year | -1.9% | -1.4M shares |
| 3 years | -7.6% | -5.8M shares |
| 5 years | -11% | -8.5M shares |
| Available history | -11% | -9.1M shares |
ALGN has 71M diluted shares, down 1.9% from a year ago, with $298M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $103.1M |
| Q2 2026 | $66.9M |
| Q1 2026 | $31.2M |
| Q4 2025 | $97.2M |
| Q3 2025 | $71.6M |
| Q2 2025 | $96M |
| Q1 2025 | $201.1M |
| Q4 2024 | $202.9M |
ALGN spent $298M buying back its own shares over the past year, down 48% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ALGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ALGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -1.4x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.2x | Net Cash |
| Q1 2025 | -1.2x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
ALGN has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ALGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.6 | Neutral |
| Stochastic | 50.8 | Neutral |
ALGN's weekly RSI is 54 (neutral) and its Stochastic is 51 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ALGN PE vs Healthcare Sector
| Metric | ALGN | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 5.8% below |
| PE % | 16 | 29 | 13 pts below |
ALGN is trading at 24x earnings, in line with the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ALGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $152.2 | 9.7% above |
| 20 week MA | $161.4 | 3.5% above |
| 50 week MA | $168.0 | 0.6% below |
| 100 week MA | $169.4 | 1.4% below |
| 200 week MA | $225.1 | 26% below |
ALGN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ALGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $277.6 | $528.0 | +90% |
| 2021 | $528.0 | $654.0 | +24% |
| 2022 | $654.0 | $203.7 | -69% |
| 2023 | $203.7 | $274.0 | +35% |
| 2024 | $274.0 | $211.4 | -23% |
| 2025 | $211.4 | $158.4 | -25% |
| 2026 YTD | $158.4 | $167.0 | +5.4% |
ALGN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.